Immunotherapy in the Asiatic population: any differences from Caucasian population? - Wikidata - awgldk - TriplyDB

Immunotherapy in the Asiatic population: any differences from Caucasian population?

Immunotherapy in the Asiatic population: any differences from Caucasian population?

http://www.wikidata.org/entity/Q55312983

about

Immunotherapy in the Asiatic population: any differences from Caucasian population?

http://www.wikidata.org/entity/Q55312983

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Immunotherapy in the Asiatic population: any differences from Caucasian population?

@en

Immunotherapy in the Asiatic population: any differences from Caucasian population?

@nl

type

label

Immunotherapy in the Asiatic population: any differences from Caucasian population?

@en

Immunotherapy in the Asiatic population: any differences from Caucasian population?

@nl

prefLabel

Immunotherapy in the Asiatic population: any differences from Caucasian population?

@en

Immunotherapy in the Asiatic population: any differences from Caucasian population?

@nl

P1433

Q55312983-6867EE72-20B0-4608-BE11-3B5D7321A9D6

P1476

Q55312983-4F9CE442-88EC-4523-AD19-503590E54A2E

P2093

Q55312983-5DB1A943-DE5A-4F21-A556-2545FDEF6A7A

Q55312983-FB432DDB-5804-44A3-A0C3-283905340801

P2860

Q55312983-062CC684-1ECD-4002-9F75-DF91707D11E5

Q55312983-07FE9DDF-4580-4013-AE13-B44C91D41B83

Q55312983-0C16538F-57E2-4668-9B57-7DDB1BD5963E

Q55312983-1088CF2B-EAE3-4044-8650-12BFEB74ECF6

Q55312983-10A1A25B-6BE2-4278-B9A1-080257E75F18

Q55312983-11100978-6DE9-4593-AC43-73D825D3657C

Q55312983-1175340D-DCF9-4957-8D6E-28A52DC3C856

Q55312983-129AC59C-16E4-4721-A4DC-C03068FD91DC

Q55312983-15DBE30A-BA9F-4C62-BAD4-F1A093E8B25D

Q55312983-162AEE1F-83A0-4F47-BBAE-49CC689D24DF

P304

Q55312983-2EF06BE9-C783-4558-A665-1807075AE3C3

P31

Q55312983-6C1EEC8C-F2BE-43F8-B525-DF4FAC20A2C1

P356

Q55312983-84E8A5E3-DB75-4502-A121-6BE610E95151

P433

Q55312983-1F971CAF-7155-4AC6-BBC0-CDACC76D86D7

P478

Q55312983-1130BBBC-45CA-48AD-A211-EEE7911DBB46

P577

Q55312983-3306B271-C7F7-40F0-99AC-B6CCB8242FE0

P698

Q55312983-6FD74ABD-60DC-4748-A5B1-0DF17FB939FB

P921

Q55312983-8BD9E343-80C0-4E0E-A6AA-608E57EEBDDA

P932

Q55312983-399B432F-E91C-41ED-B4DB-53C8D332B2EB

P356

JTD.2018.05.106

P1433

Journal of thoracic disease

P1476

Immunotherapy in the Asiatic population: any differences from Caucasian population?

@en

P2093

Lunxi Peng

http://www.w3.org/2001/XMLSchema#string

Yi-Long Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Crizotinib resistance: implications for therapeutic strategies

Radiotherapy combination opportunities leveraging immunity for the next oncology practice

Combining radiotherapy and cancer immunotherapy: a paradigm shift

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

P304

S1482-S1493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/JTD.2018.05.106

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 13

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29951300

http://www.w3.org/2001/XMLSchema#string

P921

P932

5994501

http://www.w3.org/2001/XMLSchema#string